Meet the doctor
Diana Vradii MD, RHMSUS
Dr. Vradii is a Board-Certified Rheumatologist recognized by the American Board of Internal Medicine and Rheumatology Board.
She completed Internal Medicine training at the University of Massachusetts, Worcester in 2011, followed by a Rheumatology Fellowship at Boston Medical Center in 2013.
During fellowship training, she had the privilege of learning from some of the world's leading specialists in treating rare conditions, including scleroderma and vasculitis.
In addition to clinical training, Dr. Vradii has completed Ultrasound School of North American Rheumatologists (USSONAR) musculoskeletal ultrasound training and has integrated its use into daily practice. Musculoskeletal ultrasound is a valuable tool that assists rheumatologists in diagnosing and monitoring inflammatory joint conditions and other conditions, while minimizing the need for costly imaging and avoiding radiation exposure. Dr. Vradii refers to MSK ultrasound as her ‘stethoscope’.
After relocating to Maine in 2013, Dr. Vradii joined Mid Coast Hospital, where she established a new rheumatology practice. Over the years, practice expanded and thrived, with Dr. Vradii successfully serving thousands of patients.
In 2025 Dr. Vradii transitioned to independent practice in the heart of Brunswick. She evaluates patients facing complex rheumatological conditions and strives to simplify intricate concepts. She thoughtfully informs her patients while emphasizing transparency and prioritizing patient education.
Beyond engaging in multiple roles as a physician, Dr. Vradii cherishes time spent with her family. She enjoys exploring the outdoors, listening to acoustic music and gathering with friends around a firepit.
Professional memberships
-
Kissin EY, Garg A, Grayson PC, Dubreuil M, Vradii D, York M, Simms RW. Ultrasound assessment of subcutaneous compressibility: a potential adjunctive diagnostic tool in eosinophilic fasciitis. J Clin Rheumatol. 2013 Oct;19(7):382-5. doi: 10.1097/RHU.0000000000000020. PMID: 24048117.
Challenging cases in Rheumatology and Diseases of the Immune system. March 2013. DOI:10.1007/978-1-4614-5088-7 SBN: 978-1-4614-5087-0
Dowdy CR, Xie R, Frederick D, Hussain S, Zaidi SK, Vradii D, Javed A, Li X, Jones SN, Lian JB, van Wijnen AJ, Stein JL, Stein GS. Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation. Hum Mol Genet. 2010 Mar 15;19(6):1048-57. doi: 10.1093/hmg/ddp568. Epub 2009 Dec 24. PMID: 20035012; PMCID: PMC2830828.
Stein GS, Lian JB, van Wijnen AJ, Stein JL, Javed A, Montecino M, Choi JY, Vradii D, Zaidi SK, Pratap J, Young D. Organization of transcriptional regulatory machinery in nuclear microenvironments: implications for biological control and cancer. Adv Enzyme Regul. 2007;47:242-50. doi: 10.1016/j.advenzreg.2006.12.014. Epub 2007 Mar 23. PMID: 17363043; PMCID: PMC2683591.
Vradii D, Wagner S, Doan DN, Nickerson JA, Montecino M, Lian JB, Stein JL, van Wijnen AJ, Imbalzano AN, Stein GS. Brg1, the ATPase subunit of the SWI/SNF chromatin remodeling complex, is required for myeloid differentiation to granulocytes. J Cell Physiol. 2006 Jan;206(1):112-8. doi: 10.1002/jcp.20432. PMID: 15965950.
Li X, Vradii D, Gutierrez S, Lian JB, van Wijnen AJ, Stein JL, Stein GS, Javed A. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1. J Cell Biochem. 2005 Nov 1;96(4):795-809. doi: 10.1002/jcb.20548. PMID: 16149049.
Vradii D, Zaidi SK, Lian JB, van Wijnen AJ, Stein JL, Stein GS. Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype. Proc Natl Acad Sci U S A. 2005 May 17;102(20):7174-9. doi: 10.1073/pnas.0502130102. Epub 2005 May 3. PMID: 15870195; PMCID: PMC1129117.
Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res. 2003 Sep 1;63(17):5357-62. PMID: 14500368.